Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STERITALC vs SCLEROSOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sterile talc (STERITALC) induces pleural inflammation and fibrosis, leading to adhesion of the pleural layers. This mechanism is mediated by activation of mesothelial cells and fibroblasts, resulting in release of inflammatory cytokines and growth factors.
SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of blood vessels and causing inflammation, thrombosis, and fibrosis, leading to obliteration of the injected vein.
Pleurodesis for malignant pleural effusion,Pleurodesis for recurrent pneumothorax,Pleurodesis for chylothorax (off-label)
Treatment of uncomplicated spider veins (telangiectasias) and reticular veins of the lower extremities,Treatment of small varicose veins
Sterile talc powder for intrapleural administration: 4-8 g mixed with 50-250 m L normal saline, instilled via chest tube for pleurodesis. Single dose typically used.
0.5-5 m L of 5% solution administered by intrapleural injection once daily for up to 3 days.
Not applicable; talc particles are not metabolized and remain in the pleural space indefinitely, with gradual clearance over months to years via macrophage uptake and lymphatic drainage.
60-90 minutes (clinical context: rapid elimination requires multiple daily dosing for maintenance of effect)
Talc is an inert mineral; not metabolized. Systemic absorption may lead to deposition in tissues, but no specific metabolic pathway exists.
Sodium tetradecyl sulfate is a small molecule that is not significantly metabolized; it is eliminated primarily via renal excretion.
Sterile talc (STERITALC) is not absorbed systemically following intrapleural administration. Excretion occurs locally via phagocytosis and clearance by pleural lymphatics; no significant renal, biliary, or fecal elimination applies.
Primarily renal (80-90% unchanged), minimal biliary/fecal (5-10%)
Not applicable; talc is an inorganic silicate, does not bind to plasma proteins.
20-30% (primarily to albumin)
Not applicable; talc remains at the site of administration (pleural space) with negligible systemic distribution.
0.3-0.5 L/kg (clinical meaning: moderate distribution, mainly in extracellular fluid)
Not applicable; administered via intrapleural instillation and acts locally. No systemic absorption is intended or occurs.
Oral: 10-20% (first-pass effect); subcutaneous: 70-80%; intramuscular: 75-85%; intravenous: 100%
No dose adjustment required for renal impairment.
No specific dose adjustment required; use with caution in severe renal impairment.
No dose adjustment required for hepatic impairment.
No specific dose adjustment required for Child-Pugh A or B; avoid in Child-Pugh C due to risk of toxicity.
Safety and efficacy not established in pediatric patients; use not recommended.
Not recommended for pediatric use due to lack of safety and efficacy data.
No specific dose adjustment; consider general precautions for elderly due to potential comorbidities.
No specific dose adjustment; monitor for pleural irritation and systemic effects due to increased sensitivity.
Risk of acute respiratory distress syndrome (ARDS), pneumonitis, and granulomatous inflammation secondary to talc particle absorption. Use only as a sterile, asbestos-free talc slurry or poudrage. Avoid systemic absorption.
There is no FDA black box warning for SCLEROSOL.
Use only sterile, asbestos-free talc,Monitor for respiratory distress, pneumothorax, or re-expansion pulmonary edema,Avoid in patients with empyema or active pleural infection,Caution in patients with compromised pulmonary function,Risk of fever, chest pain, and pleural effusion recurrence
Anaphylactic shock and allergic reactions,Arterial injection causing tissue necrosis,Deep vein thrombosis and pulmonary embolism,Intra-arterial injection leading to severe ischemia,Risk of anaphylaxis in patients with multiple allergies
Hypersensitivity to talc,Pleural infection or empyema,Severe respiratory insufficiency,Pregnancy and lactation (relative contraindication),Uncontrolled bronchopleural fistula
Known hypersensitivity to sodium tetradecyl sulfate,Acute thromboembolic disease,Severe peripheral arterial disease,Incompetent perforating veins without treatment of underlying reflux,Uncontrolled systemic disease (e.g., diabetes, hyperthyroidism),Local infection at the injection site,Bedridden patients
No known food interactions. Maintain normal diet unless otherwise instructed by physician.
No known food interactions. Maintain adequate hydration. Avoid alcohol for 24 hours post-treatment to minimize vasodilation.
Insufficient human data; animal studies not conducted. Sterile talc is not absorbed systemically when used for pleurodesis, thus minimal fetal exposure. However, talc may cause maternal inflammation and fever, which could theoretically increase risk of preterm labor or fetal distress in third trimester. Use in pregnancy only if clearly needed.
FDA Pregnancy Category C. Sclerosol (talc) is not absorbed systemically when used intrapleurally; however, inadvertent intravenous administration or systemic absorption may occur. Animal reproduction studies have not been conducted. Inadvertent maternal exposure could theoretically cause fetal harm. Use only if clearly needed during pregnancy; avoid during first trimester if possible.
No data on excretion into breast milk. Due to lack of systemic absorption after pleural administration, transfer into milk is unlikely. Caution advised; consider risk-benefit.
No data on excretion into breast milk. Talc is not absorbed systemically when used intrapleurally, but trace amounts may enter milk. Due to lack of studies, caution is advised. The milk-to-plasma ratio is unknown. Consider discontinuing breastfeeding or alternative agents.
No dose adjustment necessary due to minimal systemic absorption. Use standard pleurodesis dose (typically 2-5 g as slurry or poudrage).
No pharmacokinetic changes expected as systemic absorption is negligible. Standard intrapleural dosing (e.g., 2-10 g in 50-250 m L saline) may be used, but consider gestation-related pleural space changes. No dose adjustment recommended, but use lowest effective dose to minimize complications.
STERITALC (talc) is used for pleurodesis in malignant pleural effusion or recurrent pneumothorax. Administer via chest tube as a slurry or poudrage. Monitor for chest pain, fever, and hypoxia post-instillation. Ensure lung re-expansion before use to avoid trapped lung. Do not use in patients with empyema or bronchopleural fistula.
SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent used for varicose veins and telangiectasias. Avoid extravasation; tissue necrosis may occur. Use caution in patients with thrombophlebitis or hypercoagulable states. Max dose per session: 10 m L of 3% solution. Contraindicated in pregnancy and known allergy to the drug.
You may experience chest pain, fever, or shortness of breath after the procedure.,The medication causes the layers of your lung to stick together to prevent fluid or air buildup.,Report any severe pain, difficulty breathing, or signs of infection immediately.,Avoid strenuous activity and keep the chest tube site clean and dry.,Follow up with your doctor for imaging to confirm pleurodesis effectiveness.
You may experience a burning sensation at the injection site that lasts a few minutes.,Avoid strenuous activity and prolonged standing for 24-48 hours after treatment.,Wear compression stockings as directed to improve outcomes and reduce side effects.,Report any signs of infection, severe pain, or leg swelling to your doctor immediately.,Multiple sessions may be needed for complete vein closure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STERITALC vs SCLEROSOL, answered by our medical review team.
STERITALC is a Sclerosing Agent that works by Sterile talc (STERITALC) induces pleural inflammation and fibrosis, leading to adhesion of the pleural layers. This mechanism is mediated by activation of mesothelial cells and fibroblasts, resulting in release of inflammatory cytokines and growth factors.. SCLEROSOL is a Sclerosing Agent that works by SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of blood vessels and causing inflammation, thrombosis, and fibrosis, leading to obliteration of the injected vein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STERITALC and SCLEROSOL depend on the specific clinical indication. These are both Sclerosing Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STERITALC is: Sterile talc powder for intrapleural administration: 4-8 g mixed with 50-250 m L normal saline, instilled via chest tube for pleurodesis. Single dose typically used.. The standard adult dose of SCLEROSOL is: 0.5-5 m L of 5% solution administered by intrapleural injection once daily for up to 3 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STERITALC and SCLEROSOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STERITALC is classified as Category C. Insufficient human data; animal studies not conducted. Sterile talc is not absorbed systemically when used for pleurodesis, thus minimal fetal exposure. However, talc may cause mat. SCLEROSOL is classified as Category C. FDA Pregnancy Category C. Sclerosol (talc) is not absorbed systemically when used intrapleurally; however, inadvertent intravenous administration or systemic absorption may occur. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.